CPG-7909 (PF-3512676, ProMune^®): toll-like receptor-9 agonist in cancer therapy

Yanal M Murad Duke University Medical Center, Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, 401 MSRB, Research Drive, Durham, NC 27710, USA [email protected]

, PhD,

Timothy M Clay Duke University Medical Center, Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, 401 MSRB, Research Drive, Durham, NC 27710, USA [email protected]

, PhD,

H Kim Lyerly Duke University Medical Center, Duke Comprehensive Cancer Center, Departments of Surgery, Pathology and Immunology, Program in Molecular Therapeutics, 401 MSRB, Research Drive, Durham, NC 27710, USA

, MD &

Michael A Morse Duke University Medical Center, Department of Medicine, Program in Molecular Therapeutics, Comprehensive Cancer Center, Box 3233, 401 MSRB, Research Drive, Durham, NC 27710, USA

, MD

Abstract

Stimulation of toll-like receptor (TLR)9 activates human plasmacytoid dendritic cells and B cells, and induces potent innate immune responses in preclinical tumor models and in patients. CpG oligodeoxynucleotides (ODNs) are TLR9 agonists that show promising results as vaccine adjuvants and in the treatment of cancers, infections, asthma and allergy. PF-3512676 (ProMune^®) was developed as a TLR9 agonist for the treatment of cancer as monotherapy and as an adjuvant in combination with chemo- and immunotherapy. Phase I and II trials have tested this drug in several hematopoietic and solid tumors. Pfizer has initiated Phase III trials to test PF-3512676 in combination with standard chemotherapy for non-small-cell lung cancer.

Keywords::

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

CPG-7909 (PF-3512676, ProMune^®): toll-like receptor-9 agonist in cancer therapy

Information for

Open access

Opportunities

Help and information

CPG-7909 (PF-3512676, ProMune®): toll-like receptor-9 agonist in cancer therapy

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature

CPG-7909 (PF-3512676, ProMune^®): toll-like receptor-9 agonist in cancer therapy